First-ever STGD1 therapy filing at FDA with a clean Phase 3 win — approval in February 2027 is the single make-or-break event

Belite Bio is a clinical-stage company developing tinlarebant, an oral drug for Stargardt disease, which is not yet approved.

Tinlarebant, an oral small molecule that slows the inherited retinal degeneration of Stargardt disease, hit its Phase 3 primary endpoint with a 36% reduction in lesion growth rate. No treatment for STGD1 has ever been approved, and the FDA accepted the NDA with Priority Review, Breakthrough Therapy, and RMAT designations. The thesis resolves at the February 2027 PDUFA date; the central risk is that the single-arm-adjacent adolescent-focused dataset leaves regulators room to request additional evidence before granting full approval.